Search for: "US v. Coats" Results 201 - 220 of 1,082
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
27 Mar 2019, 5:28 am by Brian Cordery
The patent The relevant patent claims relate to the use of a given dosage unit of tadalafil (1-5mg), up to a maximum dose of 5mg per day, for use in sexual dysfunction (the claims are in both EPC 2000 format (a purpose-limited product claim) and in Swiss-form (a purpose-limited process claim)). [read post]
22 Mar 2009, 8:52 pm
Warner Chilcott Laboratories Ireland Ltd. et al. v. [read post]
6 Oct 2008, 3:38 am
Proctor & Gamble Co. et al. v. [read post]
31 Aug 2015, 11:12 am
Quite a way to begin an opinion, from Kremen v. [read post]
5 Nov 2016, 1:14 pm by Lawrence B. Ebert
” Id.Of legal matters:We review the grant of summary judgment de novo.See Akzo Nobel Coatings, Inc. v. [read post]
2 Dec 2013, 8:52 am by Daniel Richardson
By Andrew DelaneyState Farm Mutual Automobile Insurance Co. v. [read post]
27 Oct 2008, 2:26 pm
Thus Mann J was right on that point too.* The judge's findings that the nature of the waxed product (i) reduced the risk of charring, (ii) gave rise to a noticeable difference if a low temperature soldering iron were used and (iii) created a more easily-removable coating were not supported by the evidence. * Mann J should not have inferred that Thorn's waxed coating would probably move aside more readily with less heat being applied. [read post]
10 Jun 2014, 12:24 am by Steve Baird
By way of example, in reaching a conclusion about the alleged likelihood of confusion between PLASTI DIP and FLEXIDIP, both for rubberized plastic coating products, the TTAB would ignore the different visual impressions of the marks and the different house marks on the packaging (Performix v. [read post]
14 Apr 2017, 2:26 am
USA: Fox Television Stations, Inc. v. [read post]
26 May 2012, 8:41 pm by Mark Summerfield
Apotex Pty Ltd v AstraZeneca AB [2011] FCA 1520 (14 December 2011) Apotex Pty Ltd v AstraZeneca AB (No 2) [2012] FCA 142 (28 February 2012) Watson Pharma Pty Ltd v AstraZeneca AB [2012] FCA 200 (9 March 2012) Apotex Pty Ltd v AstraZeneca AB (No 3) [2012] FCA 265 (23 March 2012) AstraZenenca’s cholesterol drug CRESTOR will remain without generic competition in the Australian market for the foreseeable future, following a series of interlocutory decisions… [read post]
7 Jun 2017, 1:40 pm by Alex Potcovaru
Jordan Brunner and Emma Kohse provided a detailed overview of Carpenter v. [read post]